Becton Dickinson May Collaborate with Accelr8 on Rapid Dx Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Becton Dickinson has bought the rights to negotiate with Accelr8 Technology to develop its BACcel rapid diagnostic platform, Accelr8 said Thursday.
 
BD will pay Accelr8 $100,000 for the right to an exclusive negotiation period lasting through March 31, 2008, during which the companies will consider a development and commercialization program for the system. Such an agreement could include licensing rights, an equity investment, a joint development, or other type of development program, said Accelr8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.